Comprehensive Coverage on Anti‐mycobacterial Endeavour Reported in 2021
Tejas M. Dhameliya, Aanal A. Devani, Krupa A. Patel, Kashvi C. Shah
Abstract
Abstract Tuberculosis (TB) has been the highly contagious airborne disease caused by Mycobacterium tuberculosis and the major leading infectious disease with the higher upsurge of morbidity and mortality. Owing to problems in the current regimen for TB and emergence of drug resistance strains, there is a strong necessity for development of new anti‐TB drugs with better efficacy, reduced duration of action, along with improved patient compliance. Towards this, the scaffolds reported in 2021 with anti‐tubercular activity such as benzofuran, benzothiazinone, benzimidazoles, indole, piperidine, piperazine, pyrazole, pyridine, pyrimidine, pyrrolidine, quinoxaline, triazole, etc. have been critically reviewed along with their structure‐activity relationships, mode of actions with anticipations of intuitions to design the newer anti‐mycobacterial scaffolds.